|
Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add-Aspirin trial. |
|
|
Consulting or Advisory Role - Bayer Schering Pharma (Inst) |
Research Funding - Bayer Schering Pharma (Inst) |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; CV6 Therapeutics; Halozyme; Karus Therapeutics; Merck Serono; Pierre Fabre; Roche; SERVIER; Sirtex Medical |
Research Funding - Almac Group |
Travel, Accommodations, Expenses - Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Nucana |
|
|
Travel, Accommodations, Expenses - Merck |
|
|
Honoraria - Lilly; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Roche; SERVIER |
Travel, Accommodations, Expenses - Bayer; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Aurobindo; Cipla; HealthCare Global |
|
|
Consulting or Advisory Role - Tesaro |
Speakers' Bureau - Tesaro |
Travel, Accommodations, Expenses - Tesaro |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; SERVIER |
Consulting or Advisory Role - Amgen; Merck Serono; SERVIER |
Speakers' Bureau - Merck Serono |
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER |
|
|
Travel, Accommodations, Expenses - SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |